ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "caucasian"

  • Abstract Number: 1878 • ACR Convergence 2021

    Tocilizumab in Caucasian Patients with Takayasu Arteritis: Multicenter Study of 54 Patients

    Diana Prieto-Peña1, Pilar Bernabeu2, Paloma Vela3, Javier Narvaez4, Jesús Carlos Fernández-López5, Mercedes Freire6, Beatriz González-Alvarez7, Roser Solans-Laqué8, José Luis Callejas9, Norberto Ortego10, Carlos Fernández-Díaz11, Esteban Rubio Romero12, Salvador Garcia-Morillo13, Mauricio Minguez14, Cristina Carballido14, Eugenio De Miguel15, Sheila Melchor16, Eva Salgado17, Beatriz Bravo18, Susana Romero-Yuste19, Juan Salvatierra20, Cristina Hidalgo21, Sara Manrique Arija22, Carlos Romero Gomez23, Patricia Moya24, Noelia Álvarez-Rivas25, Javier Mendizábal-Mateos26, Francisco Ortiz-Sanjuán27, Ivan Perez De Pedro28, Jose L Alonso-Valdivielso29, Laura Perez-Sanchez30, Rosa Roldan31, Nagore Fernandez-Llanio32, Ricardo Gómez de la Torre33, Silvia Suarez33, Mara Jess Montesa Cabrera34, MONICA DELGADO SANCHEZ35, Javier Loricera1, Belén Atienza-Mateo36, Miguel Ángel gonzalez-Gay37 and Ricardo Blanco38, 1Hospital Universitario Marqués de Valdecilla, santander, Spain, 2Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain, 3Hospital General Universitario de Alicante, Alicante, Spain, 4Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 5Hospital Universitario Juan Canalejo, A Coruña, Spain, 6Rheumatology Service. CHU Coruña, La Coruña, Spain, 7H. NªSª de la Candelaria, Tenerife, Spain, 8Hospital Vall d'Hebron, Barcelona, Spain, 9Hospital San Cecilio, Granada, Spain, 10Medicine Department, Universidad de Granada, Granada, Spain, 11Hospital Universitario Reina Sofía, Murcia, Spain, 12HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, Seville, Spain, 13H Virgen del Rocio, Sevilla, Spain, 14H. San Juan, Alicante, Spain, 15Hospital Universitario La Paz, Madrid, Spain, 16H. 12 de Octubre, Madrid, Spain, 17Complejo Hospitalario Universitario de Ourense, Ourense, Spain, 18Hospital Universitario Virgen de las Nieves, Granada, Spain, 19Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, 20H San Juan, Alicante, Spain, 21Hospital Universitario Salamanca, Salamanca, Spain, 22Hospital Regional de Málaga, Málaga. Spain., Malaga, Spain, 23H. Regional de Malaga, Malaga, Spain, 24Hospital Sant Pau, Barcelona, Spain, 25Hospital San Agustín, Aviles, Spain, 26H. Navarra, Navarra, Spain, 27H. La Fe, Valencia, Spain, 28H. Carlos Haya, Malaga, Spain, 29H. Burgos, Burgos, Spain, 30IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, 31H. Reina Sofia, Cordoba, Spain, 32H. Arnau de Vilanova, Valencia, Spain, 33H. Asturias, Oviedo, Spain, 34Hospital Universitario Nuestra Seora de la Candelaria, Santa Cruz de Tenerife, Spain, 35H NªSª Candelaria, Tenerife, Spain, 36Group "Research in genetic epidemiology and atherosclerosis of systemic diseases and in bone metabolic diseases of the locomotor system", IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 37Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 38Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Tocilizumab (TCZ) has shown to be effective for large vessel vasculitis including Takayasu arteritis (TAK) (1-3). Most evidence in TAK comes from Asian patients.…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology